ERBB2 and neoplasm: In this respect, it has been reported that a combination of the EGFR-directed mAb C225 and the erbB2 directed mAb 4D5 or using dual EGFR/HER2 inhibitors inhibited proliferation of tumor cell lines more strongly than either mAb alone (Ye et al, 1999; Motoyama et al, 2002; Xia et al, 2002).